시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
향정신성 의약품 시장 규모, 점유율, 성장 분석 : 약물 유형별, 용도별, 약물 종류별, 질환별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Psychotropic Drugs Market Size, Share, and Growth Analysis, By Drug Type (Aripiprazole, Brexipiprazole), By Application (Anti-Psychotics, Anti-Anxiety), By Therapeutic Class, By Disease, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드 : 1831566
리서치사 : SkyQuest
발행일 : 2025년 09월
페이지 정보 : 영문 188 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,611,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,904,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,197,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계 향정신성 의약품 시장 규모는 2023년에 238억 달러로 평가되었으며, 2024년 248억 달러에서 2032년에는 344억 7,000만 달러로 성장하여 예측 기간(2025-2032년) 동안 CAGR 4.2%로 성장할 전망입니다.

세계 향정신성 의약품 시장은 정신건강 문제에 대한 인식이 높아지고 불안과 우울증의 유병률이 증가함에 따라 큰 폭으로 성장하고 있습니다. 의약품 개발 기술의 발전과 함께 헬스케어에 대한 접근성 향상도 이러한 확대에 기여하고 있습니다. 또한, 정신과 치료의 보편화 및 정신건강 프로그램 강화를 위한 정부의 지원책이 시장의 수요를 더욱 촉진하고 있습니다. 이러한 추세는 신흥국 및 재량 소득 수준의 상승에 힘입어 전 세계적으로 향정신성의약품의 사용 확대가 촉진되고 있습니다. 그 결과, 이러한 요인의 총체적 결과로서 시장 상황의 진화와 시장 잠재력이 부각되고, 기존 시장과 신흥 시장 모두에서 정신건강에 대한 노력의 중요성이 부각되고 있습니다.

목차

소개

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

향정신성 의약품 시장 규모 : 약제 종류별 & CAGR(2025-2032년)

향정신성 의약품 시장 규모 : 용도별 & CAGR(2025-2032년)

향정신성 의약품 시장 규모 : 치료 클래스별 & CAGR(2025-2032년)

향정신성 의약품 시장 규모 : 질환별 & CAGR(2025-2032년)

향정신성 의약품 시장 규모 : 유통 채널별 & CAGR(2025-2032년)

향정신성 의약품 시장 규모 & CAGR(2025-2032년)

경쟁 정보

주요 기업 개요

결론과 제안

KSM
영문 목차

영문목차

Global Psychotropic Drugs Market size was valued at USD 23.8 billion in 2023 and is poised to grow from USD 24.8 billion in 2024 to USD 34.47 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).

The global psychotropic drugs market is experiencing significant growth, propelled by a heightened awareness of mental health issues and rising incidences of anxiety and depression. Enhanced healthcare accessibility is contributing to this expansion, alongside advancements in drug development technologies. Furthermore, the increasing acceptance of psychiatric treatments and supportive government initiatives aimed at bolstering mental health programs are further driving market demand. The trend is also supported by emerging economies and a rise in discretionary income levels, facilitating greater utilization of psychotropic medications globally. As a result, these factors collectively underscore the evolving landscape and potential of the psychotropic drugs market, highlighting the importance of addressing mental health in both established and developing markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psychotropic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Psychotropic Drugs Market Segments Analysis

Global Psychotropic Drugs Market is segmented by Drug Type, Application, Therapeutic Class, Disease, Distribution Channel and region. Based on Drug Type, the market is segmented into Aripiprazole, Brexipiprazole, Olanzapine, Peliperidone Palmitate, Clozapine, Quetiapine, Chlorpromazine, Risperidone, Paroxetine, Thioridazine, Fluvoxamine and Other Drug Types. Based on Application, the market is segmented into Anti-Psychotics, Anti-Anxiety, Mood Stabilizers, Antidepressants, Stimulants, Hypnotics, Antiepileptic Drugs and Other Applications. Based on Therapeutic Class, the market is segmented into First Generation, Second Generation and Third Generation. Based on Disease, the market is segmented into Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia and Other Diseases. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market is experiencing growth driven by increased awareness surrounding mental health, bolstered by public information campaigns and support from celebrity advocates that have normalized mental health treatment. This heightened awareness has led to more frequent diagnoses of mental illnesses. Furthermore, supportive government initiatives and strategic workplace wellness programs have enhanced the accessibility and prescription rates of various psychotropic medications, such as antidepressants, anxiolytics, and antipsychotics, particularly among urban populations facing high levels of stress. The combination of these factors is fostering a greater acceptance and utilization of mental health treatments on a global scale.

Restraints in the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market faces significant constraints due to the rigorous safety and efficacy evaluations conducted by regulatory authorities, which prolong the time to market for new products. The complexity of conducting clinical trials for mental health disorders, particularly given the subjective nature of diagnoses, contributes to elevated development costs. Furthermore, the necessity for stringent post-marketing surveillance, such as monitoring for potential suicide risks associated with antidepressants, compounds these financial challenges, particularly for smaller pharmaceutical companies that may lack the resources to manage such burdens. These factors collectively hinder innovation and timely market entry in this sector.

Market Trends of the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market is increasingly shifting towards precision medicine, emphasizing personalized treatment options that utilize genetic testing and biomarker-driven approaches. Advancements in pharmacogenomics and the identification of biomarkers, such as BDNF levels and CYP450 enzyme profiles, are enhancing the ability to tailor psychotropic medications to individual patient needs, thereby reducing the trial-and-error approach traditionally associated with prescribing. This trend is further propelled by innovative companies developing psychedelic-based therapies, which are garnering significant venture capital investments and fostering partnerships within the healthcare ecosystem, ultimately driving growth and transformation in the psychotropic drugs sector.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Psychotropic Drugs Market Size by Drug Type & CAGR (2025-2032)

Global Psychotropic Drugs Market Size by Application & CAGR (2025-2032)

Global Psychotropic Drugs Market Size by Therapeutic Class & CAGR (2025-2032)

Global Psychotropic Drugs Market Size by Disease & CAGR (2025-2032)

Global Psychotropic Drugs Market Size by Distribution Channel & CAGR (2025-2032)

Global Psychotropic Drugs Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기